Invetx Announces Oversubscribed Series B Financing of $60.5 Million to Advance Portfolio of Best-in-Class Veterinary Biotherapeutics

Company positioned to bring portfolio of novel antibody product candidates through development to market approval Round includes new investors F-Prime Capital, Novo Holdings, GV and Eight Roads BOSTON, May 10,…

How Aro Biotherapeutics Is Advancing Genetic Drugs Supply

questions and answers Aro Biotherapeutics’ genetic medicine platform uses Centyrin, an artificially produced human protein, to more precisely target and treat diseased muscle and immune cells. Sign up to stay…